hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06266442 id: Mav-WGS briefTitle: M. Avium WGS During Mav-PD Treatment overallStatus: RECRUITING date: 2024-02 date: 2026-09 date: 2026-09 date: 2024-02-20 date: 2024-02-20 name: University Health Network, Toronto class: OTHER name: Western University, Canada name: Public Health Ontario Laboratory, Canada briefSummary: This is a prospective observational study using whole genome sequencing (WGS) to investigate whether new strains (other than the initially identified strain(s)) of M. avium are responsible for persistently culture positive sputum during treatment (refractory disease), or the reversion to culture positive sputum after prior conversion to negative. The study will further investigate for differences between participants living in the Toronto/York region versus participants living elsewhere.
The primary goal of this prospective observational study is to understand why some patients with M. avium lung disease have persistent or recurrent M. avium in their sputum despite treatment. The aim is to understand whether it is usually due to treatment failure or new infection. conditions: Mycobacterium Avium conditions: Mycobacterium Infections, Nontuberculous conditions: Mycobacterium Infections conditions: Nontuberculous Mycobacterial Lung Disease conditions: Respiratory Tract Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Whole genome sequencing testing measure: Proportion of patients with persistent culture-positive sputum despite antimicrobial therapy measure: Whether patients with Mav-PD have evidence of polyclonal infection as demonstrated by the presence of >1 strain of M. avium in the pre-treatment sputum or a sputum sample during treatment measure: Whether there is a source of infection from the home water environment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Health Network status: RECRUITING city: Toronto state: Ontario zip: M5G country: Canada name: Matty Mehrabi, B.Sc. M. Ed role: CONTACT phone: 416-603-5726 email: matty.mehrabi@uhn.ca name: Theodore Marras, MD role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06266429 id: STUDY00001304 briefTitle: Metabolomic Profiling of Racial Disparity overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-12-31 date: 2026-12-31 date: 2024-02-20 date: 2024-02-20 name: Olubukola Nafiu class: OTHER briefSummary: Tonsillectomy ± adenoidectomy (T\&A) is one of the most common surgical operations with over 500,000 pediatric T\&As performed annually in the United States. Unfortunately, despite advances in anesthetic and surgical techniques, moderate-severe post-tonsillectomy pain (PTP) remains a significant problem affecting up to 62% of children. PTP is thought to arise from pharyngeal mucosal inflammation, which produces local nerve irritation and pharyngeal muscle spasm. Patient factors and surgical techniques also play major roles. Race is an important phenotypic risk factor for moderately severe early PTP. The underlying molecular basis of this differential pain experience is presently unknown. This gap in knowledge means that therapies are poorly targeted and often unsuccessful. Indeed, treatment options for PTP have not advanced substantively for many years. Metabolomics provides novel opportunities to investigate common and unique "metabolic signature" of PTP through the analysis of low molecular weight compounds produced in response to tissue injury. Therefore, the central themes of this proposal are that (1) PTP is a complex process that may be determined by molecular level factors such as preoperative systemic inflammation and metabolic profile, and (2) these molecular level factors may explain the excess burden of PTP among minority children. Here the investigators seek to utilize a combined clinical, biological and untargeted metabolomics approach to identify candidate small and large serum molecules that may influence the frequency and severity of PTP in children across racial groups. This approach to exploring the molecular basis of PTP is novel and knowledge from the study should substantially enhance understanding of the mechanisms underlying pediatric PTP - and narrow the racial disparities in post-operative pain. conditions: Adenoid Hypertrophy conditions: Tonsillar Hypertrophy conditions: Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Blood collection measure: Mean fold-change of metabolomics markers by race using untargeted reverse-phase liquid-chromatographic mass spectrometry measure: Highest pain score measure: Last pain score sex: ALL minimumAge: 4 Years maximumAge: 17 Years stdAges: CHILD hasResults: False
nctId: NCT06266416 id: 115207 briefTitle: IMARA for Black Male Caregivers and Girls Empowerment (IMAGE) acronym: IMAGE overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2027-05-31 date: 2028-05-31 date: 2024-02-20 date: 2024-04-24 name: University of Illinois at Chicago class: OTHER name: University of Michigan briefSummary: The scientific premise of this research is that individual, interpersonal, and structural factors impact Black girls' sexual reproductive health outcomes (sexually transmitted infection (STI) and Human Immunodeficiency Virus (HIV)) and experience of sexual violence. This study expands STI/HIV prevention programs to include Black male caregivers, a potentially valuable yet underutilized resource to protect Black girls and reduce their exposure to STI/HIV and sexual violence. conditions: Sexually Transmitted Infections (Not HIV or Hepatitis) conditions: HIV Infections conditions: Sexual Behavior studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study will evaluate the efficacy of IMAGE with 14-18-year-old Black girls (n=300) and male caregivers (n=300) in a 2-arm individually randomized controlled trial. The researchers will compare SRH outcomes (STI incidence, self-reported sexual behavior) at 6- and 12-months among girls randomized to IMAGE or a time-matched general health promotion control program (FUEL).
The researchers will simultaneously evaluate implementation determinants (barriers, facilitators, constraints) and processes at Community Based Organizations working through the 3 steps of the implementation model (Prepare, Roll out, and Sustain). primaryPurpose: HEALTH_SERVICES_RESEARCH masking: SINGLE whoMasked: INVESTIGATOR count: 612 type: ESTIMATED name: IMARA for Black Male Caregivers and Girls Empowerment name: Time-matched control program measure: STI Incidence in Participants measure: Rate of STI History among Participants measure: Number of Participants Using Condoms measure: Number of Sexual Partners of Participants sex: ALL minimumAge: 14 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Illinois Chicago city: Chicago state: Illinois zip: 60612 country: United States name: LIsa Sharp, PhD role: CONTACT phone: 312-966-1819 email: sharpl@uic.edu name: Sue Littau role: CONTACT phone: 312.996.3932 email: slittau@uic.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06266403 id: STUDY00024154 briefTitle: Evaluating Verbal Communication in Structured Interactions: Theoretical and Clinical Implications overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2029-03 date: 2029-03 date: 2024-02-20 date: 2024-02-20 name: Penn State University class: OTHER briefSummary: The goal of this clinical trial is to learn about the effect of communicative interaction on verbal communication in people with amyotrophic lateral sclerosis (ALS) and age-matched speakers.
Participants will read words and sentences while they are in a solo setting and interactive setting. conditions: Amyotrophic Lateral Sclerosis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: PALS and age-matched adults will participate in one solo speech production task (clear speech) and three interactive tasks (structured communicative interaction, unstructured communicative interaction, and clear speech structured communicative interaction) in which they work with an unfamiliar, naive interlocutor. This study is designed to examine the differences in speech produced in the four tasks. Comparisons of speech produced by PALS and age-matched adults will clarify whether differences in speech observed across the four tasks are a function of the speech difficulties experiences by PALS.
Plans for Assignment - This is a single group study in which all participants will engage in the same tasks. primaryPurpose: BASIC_SCIENCE masking: NONE count: 300 type: ESTIMATED name: Structured Communicative Interaction name: Clear Speech name: Unstructured communicative interaction name: Clear Speech Structured Communicative Interaction measure: Formant frequencies of speech sounds measure: Intelligibility of recorded speech measure: Syntactic properties measure: Pragmatic Properties measure: Duration of speech sounds sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06266390 id: 855007 briefTitle: Engaging sgACC With TMS for Depression overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2026-01-30 date: 2026-04 date: 2024-02-20 date: 2024-04-18 name: University of Pennsylvania class: OTHER name: National Institutes of Health (NIH) briefSummary: The purpose of this study is to investigate the responses of the brain region known as the subgenual anterior cingulate cortex (sgACC) during transcranial magnetic stimulation (TMS) in individuals with depression. Specifically, investigators aim to determine whether the sgACC is engaged when TMS is delivered to specific targets and if the engagement of sgACC changes throughout a full TMS treatment intervention. To achieve this goal, the investigators will employ a combination of TMS and Magnetic Resonance Imaging (MRI) procedures.
Study participation will include completing various questionnaires, clinical assessments, receiving a full transcranial magnetic stimulation (TMS) treatment intervention (every weekday for 4-6 weeks), and undergoing MRI scans, both with and without concurrent TMS. conditions: Depression conditions: Major Depressive Disorder conditions: Persistent Depressive Disorder studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will receive rTMS to one of two targets. Participants will be randomly assigned to receive the TMS treatment intervention in one of two target conditions: half to their positive sgACC correlation target, while the remaining half to their negative sgACC correlation target. primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Participants will not be informed on which target they have been assigned to. whoMasked: PARTICIPANT count: 50 type: ESTIMATED name: Transcranial Magnetic Stimulation (TMS) measure: sgACC Blood Oxygen Level Dependent (BOLD) signal change following single-pulse fMRI-guided TMS (TMS On vs TMS Off) measure: Change in sgACC evoked response Pre/Post TMS treatment with positive and negative sgACC correlated targets sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Pennsylvania city: Philadelphia state: Pennsylvania zip: 19104 country: United States name: Almaris Figueroa-González role: CONTACT email: almaris.figuera-gonzalez@pennmedicine.upenn.edu name: Ethan Hammett role: CONTACT email: ethan.hammett@pennmedicine.upen.edu name: Desmond J Oathes, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 hasResults: False
nctId: NCT06266377 id: 11122023 briefTitle: AUT-MENU: Improving Meal Experience of Subjects With Autism Spectrum Disorder overallStatus: NOT_YET_RECRUITING date: 2024-09-01 date: 2025-06-01 date: 2025-11-30 date: 2024-02-20 date: 2024-02-20 name: University of Pavia class: OTHER name: Consiglio per la ricerca in agricoltura e l'analisi dell'economia agraria (CREA) briefSummary: The main goal of this multi-center interventional study is to improve the meal experience of children and adolescents with autism spectrum disorder trough the development of menus for collective catering targeted to their nutritional and sensory needs and the drafting of nutritional indications that can be a reference for collective catering nationwide. After an initial assessment of participants' consumption of meals in the collective service, menus adapted to their nutritional and sensory needs will be administered, and consumption between the initial and adapted menus will be compared. A population subgroup will also be selected whose caregivers will be invited to participate in a nutrition education course with the aim of providing parents of subjects with ASD, with knowledge tools to learn how to identify, manage and reduce their children's attitudes of food selectivity. conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Non-randomized multi-center intervention with a single arm. Study participants will receive new adapted canteen menus according to the nutritional and sensory needs of the target population. primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 200 type: ESTIMATED name: Administration of menus of collective catering adapted to the sensory and nutritional needs of subjects with Autism Spectrum Disorder name: Nutrition education course aimed at caregivers of individuals with Autism Spectrum Disorder measure: Food acceptance of canteen menus by individuals enrolled in the study measure: Reduction in food selectivity as a result of the targeted nutrition education course sex: ALL minimumAge: 5 Years maximumAge: 19 Years stdAges: CHILD stdAges: ADULT facility: Milano Ristorazione S.p.A. city: Milano zip: 20139 country: Italy lat: 45.46427 lon: 9.18951 facility: Istituto I.P.S.E.O.A. "Tor Carbone - A. Narducci". city: Roma zip: 00178 country: Italy lat: 41.89193 lon: 12.51133 facility: Istituto Tecnico Agrario Statale "Giuseppe Garibaldi" city: Roma zip: 00178 country: Italy lat: 41.89193 lon: 12.51133 hasResults: False
nctId: NCT06266351 id: LASIKIOP briefTitle: EVALUATION OF CATS TONOMETER PRISM IN LASIK SUBJECTS overallStatus: NOT_YET_RECRUITING date: 2024-02-12 date: 2024-06-01 date: 2024-08-01 date: 2024-02-20 date: 2024-02-20 name: Intuor Technologies, Inc. class: INDUSTRY briefSummary: The CATS Tonometer prism clinical study is intended to determine repeatability of intraocular pressure measurement in human corneas which have undergone a LASIK procedure when compared to a standard Goldmann prism, validating the human LASIK eye findings comparing CATS Tonometer and Goldmann prisms to intracameral pressure in cadaver eyes. conditions: Glaucoma conditions: Ocular Hypertension conditions: Normal Tension Glaucoma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: This is observational IOP measurement measure: IOP measurement difference between CATS and GAT in LASIK patients sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Arizona Eye Consultants city: Tucson state: Arizona zip: 85710 country: United States lat: 32.22174 lon: -110.92648 facility: Eye Specialty Group city: Memphis state: Tennessee zip: 38120 country: United States name: Sean Dodson role: CONTACT phone: 520-327-3487 email: sjmccafferty66@hotmail.com lat: 35.14953 lon: -90.04898 hasResults: False
nctId: NCT06266338 id: STU-2023-1118 briefTitle: Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix) overallStatus: RECRUITING date: 2024-03-11 date: 2025-10-31 date: 2026-10-31 date: 2024-02-20 date: 2024-03-13 name: University of Texas Southwestern Medical Center class: OTHER name: Merck Sharp & Dohme LLC briefSummary: The main purpose of this study is to gather information about an investigational drug combination, Lenvatinib in combination with pembrolizumab, that may help to treat cervical cancers. In this study, we are looking to see whether the combination of lenvatinib and pembrolizumab has any effect on slowing tumor growth in cervical cancer tumors. conditions: Cervix Cancer conditions: Cervical Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Pembrolizumab name: Lenvatinib measure: Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors v1.1 measure: Progression Free Survival (PFS) assessed by Response Evaluation Criteria in Solid Tumors v1.1 sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UT Southwestern Medical Center status: RECRUITING city: Dallas state: Texas zip: 75390 country: United States name: Annette Paulsen role: CONTACT phone: 214-648-7097 role: CONTACT email: annette.paulsen@utsouthwestern.edu lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06266325 id: 6138 briefTitle: Development and Validation of a Dementia Life Expectancy Tool overallStatus: COMPLETED date: 2010-04-01 date: 2022-12-31 date: 2022-12-31 date: 2024-02-20 date: 2024-03-04 name: University of Toronto class: OTHER name: Sunnybrook Research Institute name: Ottawa Hospital Research Institute name: ICES briefSummary: Individuals with dementia and their caregivers are faced with challenging decisions throughout the course of the disease. These decisions may be about medical care (e.g., continuation of routine cancer screening, pursuit of cardiopulmonary resuscitation, initiation of palliative care services), institutionalization (i.e., transition to a long-term care facility), or financial planning. These inherently difficult decisions are made more difficult by prognostic uncertainty. Indeed, life expectancy is challenging to predict in dementia. Consequently, prognosis is infrequently discussed by healthcare providers with individuals with dementia and their families, which compromises their ability to plan for the future. A lack of prognostic awareness makes it difficult for patients, their caregivers, and their healthcare providers to make medical decisions that strike the appropriate balance between prolonging life and promoting the quality of it. A clinical prediction tool has the promise to provide personalized and accurate estimations of life expectancy in individuals with dementia. Therefore, similar to the existing clinical prediction tools on our Project Big Life platform (www.projectbiglife.ca), we seek to create and to test a statistical model to predict survival, and to implement the model as a user-friendly, web-based calculator. The calculator will use self-reported sociodemographic, clinical, cognitive, functional, and nutritional information that is entered by patients, their caregivers, and/or their healthcare providers to output an estimated life expectancy. This estimate could inform the shared decision-making process, thereby empowering decisions that are compatible with a patient's clinical reality and concordant with their life goals. conditions: Dementia conditions: Death studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 202217 type: ACTUAL name: There is no intervention. Exposures are predictor variables of mortality. measure: Mortality sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT hasResults: False
nctId: NCT06266299 id: 2269-001 briefTitle: A Study of KK2269 in Adult Participants With Solid Tumors overallStatus: RECRUITING date: 2024-01-25 date: 2027-12 date: 2027-12 date: 2024-02-20 date: 2024-04-26 name: Kyowa Kirin, Inc. class: INDUSTRY briefSummary: This is a first-in-human study of KK2269. Part 1 and Part 2 will be conducted as a multicenter, open-label, non-randomized, dose-escalation study. Participants with advanced or metastatic solid tumors for which no standard therapy is available will be enrolled in Part 1. In Part 1, the primary objective is to assess the safety and tolerability of KK2269.
In Part 2, only participants with gastric adenocarcinoma, GEJ adenocarcinoma, esophageal adenocarcinoma, or NSCLC who have experienced at least one systemic therapy will be enrolled. In Part 2, the primary objective is to assess the safety and tolerability of KK2269 in combination with docetaxel and to determine the recommended dose(s) and dose interval(s) of KK2269 in combination with docetaxel for subsequent studies.
In both Part 1 and Part 2, participants who refuse to undergo standard therapy are also eligible. conditions: Advanced Solid Tumor conditions: Metastatic Solid Tumor conditions: Gastric Adenocarcinoma conditions: Gastroesophageal Junction Adenocarcinoma conditions: Esophageal Adenocarcinoma conditions: Non Small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 71 type: ESTIMATED name: KK2269 name: Docetaxel measure: Number of Subjects Experiencing Dose-limiting Toxicity measure: Number of Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Cancer Center Hospital East status: RECRUITING city: Kashiwa City state: Chiba zip: 277-8577 country: Japan lat: 35.86224 lon: 139.97732 facility: National Cancer Center Hospital status: RECRUITING city: Chuo-ku state: Tokyo zip: 104-0045 country: Japan lat: 35.57779 lon: 139.71685 hasResults: False
nctId: NCT06266286 id: 2022-A00233-40 briefTitle: EXOPULSE Mollii Suit & Cerebral Palsy acronym: EXOCEP overallStatus: RECRUITING date: 2023-09-13 date: 2025-06-30 date: 2025-10-30 date: 2024-02-20 date: 2024-02-20 name: Institut De La Colonne Vertebrale Et Des Neurosciences class: OTHER briefSummary: Spasticity is a frequent and debilitating symptom in patients with cerebral palsy. It can alter the patients' balance, mobility, as well as their quality of life (QoL). The available therapeutic strategies for treating spasticity and related symptoms are usually faced with limited efficacy and numerous side effects. For these reasons, non-invasive stimulation techniques, namely transcutaneous electric nerve stimulation using EXOPULSE Mollii suit, might be of help in this context. conditions: Cerebral Palsy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The investigators designes a randomized crossover, sham-controlled, double- blind trial to demonstrate the improvement of motor functions and cerebral palsy related symptoms following two weeks of daily sessions of "active" versus "sham" EXOPULSE Mollii suit. A two-week washout period should be enough to prevent a potential carry- over effect.